Tanaka Kenichi A, Mazzeffi Michael A, Strauss Erik R, Szlam Fania, Guzzetta Nina A
Department of Anesthesiology, University of Maryland Medical Center, 22 South Greene Street, Suite S8D12, Baltimore, MD, 21201, USA.
Department of Anesthesiology, Emory University School of Medicine, Atlanta, GA, USA.
J Anesth. 2016 Jun;30(3):369-76. doi: 10.1007/s00540-015-2128-3. Epub 2016 Jan 9.
Prothrombin complex concentrate (PCC) is increasingly used for acute warfarin reversal. We hypothesized that computational modeling of thrombin generation (TG) could be used to optimize the timing and dose of PCC during hemodilution induced by cardiopulmonary bypass (CPB).
Thrombin generation patterns were modeled in anticoagulated patients (n = 59) using a published computational model. Four dosing schemes were evaluated including single full dose (median, 41.2 IU/kg) of PCC before or after CPB, ½-dose before and after CPB, or 1/3-dose before CPB plus 2/3-dose after CPB. Hemodilution was modeled as 40 or 60 % dilution of factors from baseline. The lag time (s) of TG, and peak thrombin level (nM) were evaluated.
Prolonged lag time, and reduced peak TG were due to low vitamin K-dependent (VKD) factors, and pre-CPB PCC dose-dependently restored TG to near-normal or normal range. After 40 % dilution, TG parameters were similar among 4 regimens at the end of therapy. The recovery of VKD factors was less when PCC was given before CPB after 60 % dilution, but TG parameters were considered hemostatically effective (>200 nM) with any regimen. Withholding the full dose of PCC until post-CPB resulted in severely depressed TG peak (median, 47 nM) after 60 % dilution, and some supra-normal TG peaks after treatment.
Pre-CPB administration of full or divided doses of PCC prevents extremely low TG peak during surgery, and maintains hemostatic TG peaks in both 40 and 60 % hemodilution models. Although PCC's hemostatic activity appears to be highest using the full dose after CPB, hypercoagulability may develop in some cases.
凝血酶原复合物浓缩剂(PCC)越来越多地用于急性华法林逆转。我们假设凝血酶生成(TG)的计算模型可用于优化体外循环(CPB)诱导的血液稀释期间PCC的给药时间和剂量。
使用已发表的计算模型对59例抗凝患者的凝血酶生成模式进行建模。评估了四种给药方案,包括CPB前或CPB后单次全剂量(中位数,41.2 IU/kg)的PCC、CPB前后各半剂量,或CPB前1/3剂量加CPB后2/3剂量。血液稀释模拟为因子从基线稀释40%或60%。评估了TG的滞后时间(秒)和凝血酶峰值水平(nM)。
滞后时间延长和TG峰值降低是由于维生素K依赖性(VKD)因子水平低,CPB前PCC剂量依赖性地将TG恢复至接近正常或正常范围。40%稀释后,治疗结束时4种方案的TG参数相似。60%稀释后CPB前给予PCC时,VKD因子的恢复较少,但任何方案的TG参数在止血方面均有效(>200 nM)。在60%稀释后,将PCC全剂量推迟至CPB后导致TG峰值严重降低(中位数,47 nM),治疗后出现一些超正常的TG峰值。
CPB前给予全剂量或分剂量的PCC可防止手术期间TG峰值极低,并在40%和60%血液稀释模型中维持止血性TG峰值。虽然CPB后使用全剂量时PCC的止血活性似乎最高,但在某些情况下可能会出现高凝状态。